Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug Safety : ADR Category 1

Natalizumab/ocrelizumab

Recurrent urticarial erythema or disseminated nummular eczema: 2 case reports
Release Date: 10 Mar 2023 Update Date: 10 Mar 2023
Price :
$20 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug safety profile at the time of purchase.
  • A link to download a PDF version of the drug safety profile will be included in your email receipt.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top